https://www.selleckchem.com/pr....oducts/Odanacatib-(M
001). Survival curves of study sub-groups (GDD and No GDD) were significantly lower than the control group (p less then 0.001). Rejection rates in the study and control groups were 19.6% and 2.3%, respectively (p=0.01. Endothelial cell-loss in the study group was 12-22% higher than the control group at 12, 24, 36 and 48 months (p=0.049, p=0.027, p=0.200 and p=0.004). Conclusions In eyes with prior glaucoma surgery, DMEK has good early outcomes but longer-term rejection and failure rates are high. Physicians and patients sh
Like
Comment
Share
